OBJECTIVE: To assess the validity of the revised and expanded version of the Arthritis Impact Measurement Scales (AIMS2) in patients with psoriatic arthritis (PsA). METHODS: The AIMS2 was administered to all patients attending our Psoriatic Arthritis Clinic between June and December 1993. Clinical and radiological assessments were performed during the clinic visits. RESULTS: The patient population included 124 patients, 75 men and 49 women with a mean age of 48.4 years and a mean arthritis duration of 14.6 years. Most of the physical function scales as well as the pain and work scales were moderately to highly correlated with clinical measures of function (r = 0.27-0.64) and disease activity (r = 0.28-0.50), but they were not correlated with measures of disease severity. The psychosocial scales were poorly correlated with all clinical measures. CONCLUSION: Our data suggest that, like the original AIMS, the AIMS2 is valid for use as an adjunct outcome measure for clinical trials in PsA.
OBJECTIVE: To assess the validity of the revised and expanded version of the Arthritis Impact Measurement Scales (AIMS2) in patients with psoriatic arthritis (PsA). METHODS: The AIMS2 was administered to all patients attending our Psoriatic Arthritis Clinic between June and December 1993. Clinical and radiological assessments were performed during the clinic visits. RESULTS: The patient population included 124 patients, 75 men and 49 women with a mean age of 48.4 years and a mean arthritis duration of 14.6 years. Most of the physical function scales as well as the pain and work scales were moderately to highly correlated with clinical measures of function (r = 0.27-0.64) and disease activity (r = 0.28-0.50), but they were not correlated with measures of disease severity. The psychosocial scales were poorly correlated with all clinical measures. CONCLUSION: Our data suggest that, like the original AIMS, the AIMS2 is valid for use as an adjunct outcome measure for clinical trials in PsA.
Authors: Raymond A H M Swinkels; Lex M Bouter; Rob A B Oostendorp; Cornelia H M van den Ende Journal: Rheumatol Int Date: 2005-06-24 Impact factor: 2.631
Authors: Dinesh Khanna; Tracy Frech; Puja P Khanna; Robert M Kaplan; Mark H Eckman; Ron D Hays; Shaari S Ginsburg; Anthony C Leonard; Joel Tsevat Journal: Health Qual Life Outcomes Date: 2010-10-01 Impact factor: 3.186
Authors: William Tillett; Ade Adebajo; Mel Brooke; Willemina Campbell; Laura C Coates; Oliver FitzGerald; Laure Gossec; Philip Helliwell; Sarah Hewlett; Jana James; Patricia Minnock; Aisling Reast; Dennis O'Sullivan; Maarten de Wit; Neil McHugh Journal: Curr Rheumatol Rep Date: 2014-05 Impact factor: 4.592